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Abstract
This brief communication provides information to those developing 
monitoring plans for serious adverse events (SAE’s) following 
regulatory approval of a new drug. In addition, we (1) illustrate 
how many patients would need to be treated in order to have high 
confidence of seeing at least 1 pre-specified SAE, (2) show that 
absence of proof of a SAE is not proof of absence of that SAE, and 
(3) identify statistical methodology that could be used for formal 
statistical monitoring of SAE’s.
Another document [3] represents current thinking of the FDA 
on guidance for industry oversight of clinical Investigations from a 
risk-based approach to monitoring. The guidance does not create or 
confer any rights for or on any person and does not operate to bind 
FDA or the public. A company can use an alternative approach if 
the approach satisfies the requirements of the applicable statutes and 
regulations. If the company wants to discuss an alternative approach, 
they may contact the FDA staff responsible for implementing the 
guidance. If the company cannot identify the appropriate FDA staff, 
they may call the appropriate number listed on the title page of the 
guidance.
Yet another document [4] describes the FDA Adverse Event 
Reporting System (FAERS) which is a database that contains 
information on adverse event and medication error reports 
submitted to FDA. The database is designed to support FDA’s post-
marketing safety surveillance program for drug and therapeutic 
biologic products. The informatic structure of the FAERS database 
adheres to the international safety reporting guidance [5] issued by 
the International Conference on Harmonisation ICH E2B. Adverse 
events and medication errors are coded to terms in the medical 
dictionary for regulatory activities (MEDRA) [6] terminology.
Executing a RBMP for a newly approved drug will require 
summarization of individual AE’s, particularly SAE’s as they 
accumulate. Table 1, table 2 and table 3 provide relevant information 
about AE’s.
Number of Treated Patients needed to have High Confidence 
of observing at least 1 AE
Table 1 gives the number of patients that would need to be treated 
with a drug in order to have 100(1 - α)% confidence of observing at 
least (≥) 1 occurrence of a specific AE given that the true AE rate 
among treated patients is P.
For example, if the fraction of a population who would devel op 
an adverse event upon treatment with a drug at a given dose were 
0.1%, one would require 4,604 (Table 1) patients to be treated with 
the drug at the given dose in order to have 99% confidence of ob-
serving at least one patient with the adverse event. If one required a 
greater degree of certainty, say 99.99%, about 10,000 patients would 
need to be treated.
Introduction
Regardless of the efforts of a pharmaceutical company and of 
the US Food and Drug Administration (FDA) to identify harmful 
side effects prior to regulatory approval of a new drug, it is not 
possible to identify all such serious adverse events (SAE’s). There 
are many reasons for this; chief among them is the fact that the 
number of patients in clinical development programs of new drugs 
to prove efficacy are inadequate to detect rare SAE’s. It is therefore 
in a company’s best interest to develop a post marketing risk based 
monitoring plan (RBMP) of their drug as it is made available to 
patients through physician prescriptions after regulatory approval.
In developing a post marketing RBMP for a specific drug, 
discussions with the FDA are helpful and essential as are FDA 
Guidelines regarding a RBMP. The first four references of this 
document provide links to relevant FDA documents. There is a 
document [1] that identifies postmarketing requirements and 
commitments. Some of the studies listed may be required; others 
may be clinical trials a sponsor has committed to conduct – often 
conditional on approval.
Another document [2] discusses postmarketing surveillance 
programs, which include clinical trials conducted after regulatory 
approval to gather additional information on safety as well in some 
cases specific questions of efficacy. The FDA maintains a system of 
postmarketing surveillance and risk assessment programs to identify 
adverse events (AE’s) that did not appear prior and during the drug 
approval process. FDA monitors AE’s and uses the information 
collected to update drug labeling – and on some occasions to 
reevaluate the approval or marketing decision.
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Absence of proof is not proof of absence
Table 2 and table 3 provide exact confidence intervals (CIs) on 
the true incidence (P = 0.001 or 0.005) of a rare serious adverse event 
(SAE) under various scenarios. In those tables, n = number treated, 
nP = expected number of SAEs, P(X ≥ 1) = Probability of at least 1 
SAE among n patients; Outcome = probable number of SAEs among 
n patients.
Early on in the monitoring for adverse events (AE’s) of a newly 
approved drug, it is unlikely to have even 1 report of a rare serious 
adverse event (SAE). For example out of the first 150 patients exposed 
to the drug, the probability of observing no patient with an adverse 
event given that the true inci dence in the population is 0.1% is 0.861. 
It is therefore likely that among 150 patients treated with the drug, 
there is an observed incidence of 0% (0/150). An exact 95% confidence 
interval [7] based on the 0/150 data ranges from 0% to 2.43% (Table 2 
and Table 3). If what was known about the mechanism of action, the 
pharmacology and/or toxicol ogy of the drug suggested certain unto-
ward adverse events were possible, and one monitored specifically for 
such events, the fact that no such events were observed among 150 
treated patients does not mean that the true incidence of such events 
is 0 – since the upper limit of the 95% con fidence interval is 2.4%. As 
Dr. Paul Leber (former head of the CNS medical Review Division at 
FDA) often said “Absence of proof is not proof of absence”.
Monitoring adverse event rates as data accumulates
Table 1 illustrates how many patients would need to be treated 
before one has high confidence of seeing at least one rare AE. Table 
2 and table 3 illustrate that zero occurrences of an AE of interest 
from patients treated in the post marketing life of a compound 
does not allow one to conclude that the incidence of that AE is zero. 
For example, from table 3, 0 SAEs among 1,000 patients treated is 
consistent with the true SAE rate being as high as 0.37% with 95% 
confidence and as high as 0.53% with 99% confidence.
Procedures exist that permit formal sequential, statistical 
monitoring of AE’s of a drug in post-marketing as data accumulate 
(spontaneous reports). The methods of Schultz et al. [8], Fleming 
[9,10], Coe and Tamhane [11] or Peace [12,13] or Jennison and 
Turnbull [14] may be adapted for monitoring post-marketing AE’s.
There are challenges in doing this: (1) the referenced procedures 
were developed for group sequential monitoring given a fixed, 
specified total number of patients to be treated. The analyses are to be 
conducted at each of a fixed number of stages, where the number of 
patients accrued between stages is usually taken to be the total number 
of patients to be treated divided by the number of analysis stages. 
Clearly in monitoring post-marketing AE’s the number of patients 
to be treated is not known nor is it fixed. However, for monitoring 
purposes, one could develop a statistical monitoring plan based on 
a targeted number of patients to be treated within specified intervals 
of time. The intervals may be more frequent in the first year of post-
marketing say, than in subsequent years. (2) Other challenges are 
what are the numerator and denominator of the incidence estimate at 
any particular point in time? This will require the company to use its 
own spontaneous reporting system as well as the FDA adverse event 
reporting system (FAERS).
Summary
This commentary has provided information to those developing 
monitoring plans for SAE’s following regulatory approval of a new 
drug. In addition, we have (1) illustrated how many patients would 
need to be treated in order to have high confidence of seeing at least 
1 pre-specified SAE, (2) shown that absence of proof of a SAE is not 
proof of absence of that SAE, and (3) identified methodology that 
could be used for formal statistical monitoring.
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